Akebia Therapeutics

190 articles with Akebia Therapeutics

• Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication

  10/15/2019

  CMS continues to deny Medicare beneficiaries with chronic kidney disease full access to this innovative therapy

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct. 2, 2019

  10/2/2019

  Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees options to purchase an aggregate of 43,600 shares of Akebia’s common stock on September 30, 2019, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

  9/24/2019

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will present at the 2019 Cantor Global Healthcare Conference at 8:55 a.m. ET on Thursday, October 3, 2019 in New York City.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sept. 4, 2019

  9/4/2019

  Akebia Therapeutics, Inc. granted eight newly-hired employees options to purchase an aggregate of 277,250 shares of Akebia’s common stock on August 30, 2019, including an option to purchase 250,000 shares granted to Steven K. Burke, M.D., Akebia’s newly-hired Senior Vice President, Chief Medical Officer.

• Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

  9/3/2019

  INNO2VATE and PRO2TECT now fully enrolled; Company continues to expect to report top-line study results in Q2 of 2020 and mid-2020, respectively, subject to accrual of MACE

• Akebia Therapeutics to Participate in Upcoming Investor Conferences - Aug. 9, 2019

  8/9/2019

  Akebia Therapeutics, Inc. announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following investor conferences

• Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

  8/8/2019

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today reported financial results for the second quarter ended June 30, 2019.

• Akebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par Pharmaceutical

  8/5/2019

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion & BF Biotech, Inc., have entered into a Settlement and License Agreement (Agreement) with Par Pharmaceutical, Inc., an Endo International company (Par).

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug. 2, 2019

  8/2/2019

  Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 120,350 shares of Akebia’s common stock on July 31, 2019, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics to Report Second Quarter 2019 Financial Results

  7/25/2019

  Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, August 8th to discuss its second quarter financial results and recent business updates.

• Akebia Therapeutics Announces Submission of Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC

  7/23/2019

  JNDA Submission Represents First Regulatory Submission for Marketing Approval of Vadadustat

• Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners

  7/11/2019

  Akebia Therapeutics, Inc. announced that John P. Butler, President and Chief Executive Officer of Akebia, has been elected Chair of Kidney Care Partners (KCP), the nation’s largest kidney care coalition comprised of patient advocates, dialysis professionals, care providers, researchers and manufacturers.

• Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan

  7/10/2019

  Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2019

  7/2/2019

  Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted eight newly-hired employees options to purchase an aggregate of 47,850 shares of Akebia’s common stock on June 28, 2019, as inducements material to each such employee’s entering into employment with Akebia.

• Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease

  6/11/2019

  AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 4, 2019

  6/4/2019

  Akebia Therapeutics, Inc. granted 14 newly-hired employees options to purchase an aggregate of 344,200 shares of Akebia’s common stock on May 31, 2019, including an option to purchase 250,000 shares granted to Dell Faulkingham, Akebia’s newly-hired Senior Vice President, Chief Commercial Officer.

• Akebia Therapeutics to Participate in Upcoming Investor Conferences - May 29, 2019

  5/29/2019

  Akebia Therapeutics, Inc. announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following investor conferences

• Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

  5/9/2019

  Akebia Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019. The company also announced full enrollment of its global Phase 3 INNO2VATE studies for vadadustat, that it has bolstered its commercial capabilities with the addition of Dell Faulkingham as Senior Vice President, Chief Commercial Officer, and appointed Steven K. Burke, M.D., as Senior Vice President, Chief Medical Officer.

• Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

  5/2/2019

  Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease

• Akebia Therapeutics to Report First Quarter 2019 Financial Results

  4/30/2019

  Akebia Therapeutics, Inc. announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 2019, before the opening of the financial markets.